Find Funding Opportunities

NIH Extramural Response to Natural Disasters and Other Emergencies

In emergency situations, the NIH’s immediate concern is for the health and safety of people and animals in the programs we oversee.  Visit the NIH Extramural Response to Natural Disasters and Other Emergencies web page for biomedical research community resources, including NIH Guide Notices and other information of particular relevance to investigators and their institutions, links to web pages listing NIH’s response to certain major events (past and present); and links to similar web sites from other Federal agencies.

 COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related notices of funding opportunities (NOFOs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed. Search the Closed Opportunities tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

For more focused results add quotes to indicate parameters. Example format: "search term".

Displaying 1 - 10 of 23 Open Funding Opportunities
Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)
Expiration Date: Saturday, January 8, 2028
NOFO Number: PA-25-150
Wednesday, January 8, 2025
Notice Type: PA
The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing mechanistic clinical trials or studies or basic experimental studies with humans (BESH) will be considered for funding. For information on the types of clinical trial that are within scope of this funding opportunity announcement, refer to Funding Opportunity Description, below.
Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)
Expiration Date: Tuesday, February 1, 2028
NOFO Number: PAR-25-326
Wednesday, December 18, 2024
Notice Type: PAR
The purpose of this NOFO is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.
PAR-25-327 Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
Expiration Date: Saturday, October 9, 2027
NOFO Number: PAR-25-327
Wednesday, December 18, 2024
Notice Type: PAR

The purpose of this NOFO is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

PAR-25-326 Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)
Expiration Date: Tuesday, February 1, 2028
NOFO Number: PAR-25-326
Wednesday, December 18, 2024
Notice Type: PAR

The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)
Expiration Date: Saturday, November 13, 2027
NOFO Number: PAR-25-215
Monday, December 2, 2024
Notice Type: PAR
The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.
Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
Expiration Date: Saturday, November 13, 2027
NOFO Number: PAR-25-216
Monday, December 2, 2024
Notice Type: PAR
The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
Expiration Date: Friday, November 20, 2026
NOFO Number: PAR-25-052
Wednesday, November 20, 2024
Notice Type: PAR
This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
Expiration Date: Monday, September 6, 2027
NOFO Number: PAR-25-133
Tuesday, November 12, 2024
Notice Type: PAR
This announcement encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).
NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
Expiration Date: Saturday, March 7, 2026
NOFO Number: PAR-25-049
Thursday, November 7, 2024
Notice Type: PAR
This announcement (NOFO) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.
NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
Expiration Date: Saturday, January 8, 2028
NOFO Number: PAR-25-234
Thursday, November 7, 2024
Notice Type: PAR
The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in postdoctoral position. Based on the early timeframe of eligibility, and the discouragement of inclusion of preliminary data, this NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early fellowship application and timely completion of mentored training of the postdoctoral candidate in a single environment.
Export to:
A maximum of 400 records can be exported.